Sathgen Therapeutics

What Sathgen Therapeutics does

Sathgen Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule therapeutics for difficult-to-treat cancers and viral infections. Founded in 2007 as a division of Godavari Biorefineries Limited (part of the Somaiya Group) in Mumbai, India, Sathgen operates R&D facilities in India and a newly incorporated US subsidiary, Sathgen Therapeutics LLC, in Princeton, New Jersey (December 2025). Its lead asset MSP008-22 was identified after synthesis and screening of over 10,000 derivatives and has demonstrated in vitro and in vivo efficacy against triple-negative breast cancer and prostate cancer, alongside anti-metastatic, anti-stem cell, and chemosensitizing properties that improve the efficacy and lower the toxicity of Carboplatin and Cisplatin. MSP008-22 has completed Phase I clinical trials in patients with advanced solid tumors and in healthy volunteers with no serious adverse events reported. The broader pipeline comprises four drug series—MSP, SBGBL, LSPGBL (12 candidates), and METGBL (26 candidates)—representing over 40 preclinical compounds targeting TNBC, prostate, oral, glioblastoma, hepatic, cervical, colon, and lung cancers, with additional anti-SARS-CoV-2 data comparable to Remdesivir.

Intellectual property comprises 15+ granted patents covering MSP008-22 and Cleistanthin A synthesis across the US, Japan, Europe, and multiple emerging markets, with protection extending through 2040+. Sathgen's business model is explicitly pre-revenue and centered on out-licensing intellectual property, co-development partnerships, and strategic equity investment from pharmaceutical companies and research organizations. The company pursues enterprise business development through direct outreach, industry conferences (Pharma Partnering Summits in Boston and San Diego), and a scientific advisory board that includes Dr. Razelle Kurzrock (precision oncology, MD Anderson PREDICT protocol) and Dr. Massimo Cristofanilli (metastatic breast cancer, Weill Cornell Medicine). CRO service providers—including Eurofins Advinus, Aragen, Reliance Life Sciences, and Clinexel Life Sciences—support API development, safety/toxicology, pharmacokinetics, preclinical efficacy, formulation, and Phase I execution. In December 2025, Sathgen Therapeutics LLC was incorporated in Princeton to facilitate global IP out-licensing and accelerate clinical development; Dr. Padmaja Ganapathy was appointed CEO and Dr. Sendurai Mani transitioned to Chief Scientific Advisor.

Name

Sathgen Therapeutics

Legal name

Sathgen Therapeutics, LLC

Website

https://sathgentherapeutics.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Sathgen Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for hard-to-treat cancers, with lead candidate MSP008-22 having completed Phase I trials. The company pursues global IP out-licensing and pharmaceutical partnerships to advance a 40+ compound pipeline.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Clinical-stage biotechnology
• Small molecule therapeutics
• Oncology drug development
• Anti-cancer drug pipeline
• Pharmaceutical out-licensing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing Agreements: The company seeks regional or global licensing opportunities for MSP008-22 and pipeline compounds as a primary revenue strategy. Out-licensing of intellectual property to pharmaceutical companies for development and commercialization.
2. Co-Development Partnerships: Joint development programs with pharmaceutical partners including shared investment and risk mitigation strategies, generating revenue through partnership contributions and future royalties.
3. Strategic Investment: Equity partnerships with pharmaceutical and biotech companies providing capital infusion and shared growth opportunities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Sathgen Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule therapeutics for hard-to-treat cancers and viral infections. Its lead compound MSP008-22, identified from over 10,000 synthesized derivatives, has completed Phase I clinical trials in patients with advanced solid tumors and healthy individuals, demonstrating efficacy against triple-negative breast and prostate cancers plus anti-SARS-CoV-2 activity comparable to Remdesivir. The pipeline includes 40+ preclinical compounds spanning SBGBL, LSPGBL, and METGBL series.

Product overview

Sathgen Therapeutics is a clinical-stage biotechnology company developing a diversified portfolio of anti-cancer and anti-viral therapeutics. The core pipeline consists of four drug series: MSP (lead candidate MSP008-22 in Phase I trials), SBGBL, LSPGBL (12 candidates), and METGBL (26 candidates), collectively representing over 40 preclinical compounds targeting multiple cancer types including triple-negative breast cancer, prostate cancer, and various solid tumors. MSP008-22 is the lead first-in-class therapeutic that has completed Phase I clinical trials, while the company also holds patents for Cleistanthin A synthesis. The company operates as a division of Godavari Biorefineries Limited with facilities in Mumbai, India and Princeton, New Jersey.

Differentiator

Problem solved

Functional benefit

Products and services

• MSP008-22 Lead anti-cancer and anti-viral drug candidate. First-in-class small molecule therapeutic with novel mechanism of action that completed Phase I clinical trials in patients with advanced solid tumors and healthy individuals. Demonstrated efficacy against triple-negative breast cancer and prostate cancer, anti-cancer stem cell and anti-metastatic activity, and anti-SARS-CoV-2 potential comparable to Remdesivir. Designed for out-licensing or co-development with pharmaceutical partners for global commercialization.
• SBGBL Anti-cancer compound selected from 116 candidates based on safety and efficacy. Demonstrated anti-cancer activity across multiple cancer types including triple-negative breast, prostate, oral, glioblastoma, hepatic, cervical, colon, and lung cancers. Part of Sathgen's out-licensing pipeline offering for pharmaceutical partners.
• LSPGBL (LSP-derived candidates) Series of SAR-positive molecules that inhibit cancer stem cell activity by targeting survival pathways. Twelve lead LSP-derived candidates have been identified with strong anti-cancer activity and no observed toxicity across multiple cancer types. Available for out-licensing.
• METGBL (MET-derived candidates) Series of SAR-active, potential best-in-class molecules developed from two tyrosine kinase inhibitors. Twenty-six MET-derived candidates currently under evaluation for toxicity and anti-cancer efficacy. Part of Sathgen's broader oncology pipeline.
• Cleistanthin A and derivatives Plant-derived natural compound and its synthetic derivatives with anti-cancer properties. Patents granted in multiple jurisdictions including India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada. Foundation of Sathgen's chemistry IP platform.

Quantifiable outcome

• Tumor growth inhibition demonstrated in triple-negative breast cancer xenograft studies with MSP008-22 alone or in combination with Carboplatin
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor.

• Eurofins AdvinusminorImplementation/ SI/ Consulting PartnerService provider for API Development & Synthesis, Safety and Toxicity studies, and Pharmacokinetics studies.
• Aragen (formerly GVK)minorImplementation/ SI/ Consulting PartnerService provider for preclinical oncology in vivo efficacy studies.
• GV Research PlatformminorImplementation/ SI/ Consulting PartnerService provider for Pharmacokinetics studies.
• THSTIminorImplementation/ SI/ Consulting PartnerService provider for COVID in vivo efficacy studies.
• Delnova HealthcareminorImplementation/ SI/ Consulting PartnerService provider for Formulation development.
• Clinexel Life SciencesminorImplementation/ SI/ Consulting PartnerContract research organization that conducted Phase 1a clinical trials.
• Reliance Life SciencesminorImplementation/ SI/ Consulting PartnerService provider for Bioanalysis of Clinical Trial Samples for Safety, Tolerability, and Pharmacokinetics.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bexion Pharmaceuticals: Clinical-stage oncology company developing novel small molecule therapeutics with early-stage assets and a partner-seeking business model, comparable in size and stage to Sathgen.
• SELLAS Life Sciences: Clinical-stage oncology biotech with multiple small molecule and peptide programs in development, similar pre-commercial stage and partnership-oriented strategy to Sathgen.
• Iterion Therapeutics: Clinical-stage oncology company developing small molecule therapeutics with novel mechanisms of action, similar profile to Sathgen in target indications and partnership-driven development approach.
• Moleculin Biotech: Clinical-stage small molecule oncology company with early-stage assets targeting hard-to-treat cancers, comparable in size, stage, and partner-seeking business model to Sathgen.
• Lantern Pharma: Clinical-stage oncology biotech developing small molecule therapeutics using AI-driven drug discovery, with multiple programs in preclinical and early clinical stages and a similar out-licensing/partnership-focused business model.
• Aprea Therapeutics: Clinical-stage oncology company developing small molecule therapeutics with novel mechanisms of action, focused on cancers with high unmet need and similarly pre-revenue with partnership-driven commercialization plans.

Broad incumbents

• Compugen: Clinical-stage drug discovery company using computational platforms to identify novel therapeutic targets in oncology and immunology, with a broader pipeline and partnership-driven model than Sathgen.
• Schrödinger: Established computational drug discovery platform with a portfolio of wholly-owned and partnered preclinical/clinical-stage small molecule therapeutic programs, a broader and more mature presence in the same space as Sathgen's small molecule discovery work.

Emerging players

• Inceptor Bio: Early-stage oncology biotech developing novel cell therapies and small molecule therapeutics, comparable in stage and emerging pipeline approach to Sathgen's preclinical/Phase I profile.
• Vyriad: Clinical-stage oncology biotech with multiple small molecule and biologic programs in development, similar pre-revenue scale and partnership-focused approach to Sathgen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sathgen Therapeutics